AC
TGTX icon

Athanor Capital’s TG Therapeutics TGTX Stock Holding History

Athanor Capital’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-59,620
Closed -$2.87M – 754
2021
Q1 		$2.87M Sell
59,620
-31,387
-34% -$1.51M 0.07% 181
2020
Q4 		$4.73M Buy
91,007
+24,649
+37% +$833K 0.11% 128
2020
Q3 		$1.78M Sell
66,358
-46,821
-41% -$1.08M 0.07% 153
2020
Q2 		$2.21M Buy
+113,179
New +$1.82M 0.11% 109
2020
Q1 		– Sell
-33,100
Closed -$367K – 331
2019
Q4 		$367K Buy
+33,100
New +$252K 0.02% 280
2019
Q3 		– Sell
-22,900
Closed -$198K – 231
2019
Q2 		$198K Buy
+22,900
New +$173K 0.03% 132

Other funds holding TGTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

Athanor Capital's TGTX Position: Q2 2021 in Review

Athanor Capital sold out of TG Therapeutics (TGTX) in Q2 2021, closing a stake of 59,620 shares — an estimated $2.87M sold.

Athanor Capital first reported a position in TGTX in Q2 2019 and held it in 6 quarters. The position peaked at $4.73M in Q4 2020. 237 funds tracked by Wall St. Rank hold TGTX as of Q2 2021.

  • Athanor Capital reported no remaining TG Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Athanor Capital sold 59,620 TG Therapeutics shares in Q2 2021, an estimated $2.87M.
  • Athanor Capital first reported a position in TG Therapeutics in Q2 2019 and held it in 6 quarters.
  • Athanor Capital's TG Therapeutics position peaked at $4.73M in Q4 2020.
  • 237 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2021.

Based on Athanor Capital's 13F filing for Q2 2021, filed 16 Aug 2021.